BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-05
211 industry Phase 2/3 trial readout(s) and 35 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-05 est. | P1/P2 | InnoUp Farma S.L. | NCT04163562 Oral Immunotherapy for Peanut Allergic Patients | Peanut Allergy | recruiting | 50 |
| 2025-05 est. | P2 | Tessa Therapeutics | NCT04268706 Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | Hodgkin Lymphoma, Adult; Hodgkin Disease Recurrent; Hodgkin Disease Refractory; Hodgkin Disease, Ped | active not recruiting | 97 |
| 2025-05 est. | P2 | Kyowa Kirin, Inc. | NCT04745234 Mogamulizumab Q4week Dosing in Participants With R/R CTCL | Cutaneous T-Cell Lymphoma, Relapsed; Cutaneous T-Cell Lymphoma Refractory | unknown | 34 |
| 2025-05 est. | P2 | Avobis Bio, LLC | NCT04847739 Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II) | Perianal Fistula; Crohn's Disease | unknown | 60 |
| 2025-05 est. | P3 | Romark Laboratories L.C. | NCT05157243 Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness | COVID-19 | withdrawn | |
| 2025-05 est. | P3 | TYK Medicines, Inc | NCT05382728 Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | NSCLC; EGFR Activating Mutation | recruiting | 680 |
| 2025-05 est. | P2 | Hepion Pharmaceuticals, Inc. HEPA | NCT05402371 A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis | Nonalcoholic Steatohepatitis (NASH); Fibrosis, Liver; NAFLD | unknown | 120 |
| 2025-05 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05410730 A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC | High-risk NMIBC | recruiting | 150 |
| 2025-05 est. | P3 | Blau Farmaceutica S.A. | NCT05704894 Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens | Anemia; Neoplasms; Chemotherapeutic-Induced Anemia | unknown | 320 |
| 2025-05 est. | P1/P2 | Shanghai Blueray Biopharma Co., Ltd. | NCT05749549 Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | Advanced Cancer; Follicular Lymphoma; Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma | unknown | 191 |
| 2025-05 est. | P1/P2 | RemeGen Co., Ltd. | NCT05804526 A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | Advanced Solid Tumours | unknown | 82 |
| 2025-05 est. | P2 | Mundipharma Research Limited | NCT05835479 Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults | Pneumocystis Pneumonia | recruiting | 50 |
| 2025-05 est. | P2 | Jemincare | NCT05967520 JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | unknown | 48 |
| 2025-05 est. | P3 | Pharmbio Korea Co., Ltd. | NCT06154187 Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis | Osteoporosis | unknown | 60 |
| 2025-05 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06237400 A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors. | KRAS G12C Mutant Advanced Solid Tumors | unknown | 110 |
| 2025-05 est. | P2 | ImmuneMed, Inc. | NCT06306339 A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) | Moderate to Severe Rheumatoid Arthritis | unknown | 60 |
| 2025-05 est. | P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06315426 A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). | Allergic Rhinitis | active not recruiting | 240 |
| 2025-05 est. | P1/P2 | Technophage, SA | NCT06370598 Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia | Pneumonia, Ventilator-Associated | unknown | 15 |
| 2025-05 est. | P1/P2 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | NCT06438809 Umbilical-Cord-Derived Mesenchymal Stem Cells Injection for Chronic Radiation Proctitis | Chronic Radiation Proctitis | unknown | 24 |
| 2025-05 est. | P1/P2 | Shanghai Mabgeek Biotech.Co.Ltd | NCT06765005 IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients | Atopic Dermatitis | recruiting | 24 |
| 2025-05 est. | P3 | PharmaResearch Co.,Ltd | NCT06779071 Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis. | Knee Osteoarthritis | enrolling by invitation | 260 |
| 2025-05-01 | P3 | Curonix LLC | NCT02725554 Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine | Migraine | withdrawn | |
| 2025-05-01 | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04083534 First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | Relapsed Multiple Myeloma; Refractory Multiple Myeloma | completed | 43 |
| 2025-05-01 est. | P2/P3 | Advicenne Pharma | NCT04147871 Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children | Cystinuria | withdrawn | |
| 2025-05-01 est. | P3 | RDC Clinical Pty Ltd | NCT06006416 Effect of Fenugreek Fibre on Gut Microbiome | Gut Microbiome | withdrawn | |
| 2025-05-01 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06007417 A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency | GHD | unknown | 162 |
| 2025-05-01 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06024967 A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency | GHD | unknown | 180 |
| 2025-05-01 est. | P2/P3 | LumiThera, Inc. | NCT06229665 Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) | Dry Age-related Macular Degeneration | unknown | 75 |
| 2025-05-01 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06384547 A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease | completed | 231 |
| 2025-05-01 | P2 | Sutro Biopharma, Inc. STRO | NCT06555263 Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Lung Cancer; Lung Cancer Metastatic; Lung Cancer, Nonsmall Cell; Lung Cancer Non-Small Cell Stage II | withdrawn | |
| 2025-05-02 | P1/P2 | JCR Pharmaceuticals Co., Ltd. | NCT04453085 An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I) | Mucopolysaccharidosis I | completed | 14 |
| 2025-05-02 | P3 | AbbVie ABBV | NCT05216263 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migr | Chronic Migraine | completed | 75 |
| 2025-05-02 | P2 | Hoffmann-La Roche | NCT05548556 A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy (FSHD) | completed | 51 |
| 2025-05-02 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT05639894 Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older | Respiratory Syncytial Virus Immunization | completed | 865 |
| 2025-05-02 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05994378 To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects | Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Su | completed | 317 |
| 2025-05-02 | P2 | Boehringer Ingelheim | NCT06558344 A Study to Test Different Doses of BI 1569912 in People With Depression | Depressive Disorder, Major | completed | 225 |
| 2025-05-03 | P3 | Colgate Palmolive CL | NCT06957249 Clinical Study to Evaluate the Tooth Whitening Efficacy | Whitening | completed | 80 |
| 2025-05-05 | P3 | Biotest | NCT05531149 Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia | Respiratory Infection; Pneumonia; Community-acquired Pneumonia; Acute Respiratory Distress Syndrome; | terminated | 107 |
| 2025-05-05 | P2 | Neuvosyn Laboratories, LLC | NCT05712421 A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism | Hypothyroidism | completed | 303 |
| 2025-05-05 | P3 | LEO Pharma | NCT05958407 A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Thera | Atopic Dermatitis; Atopic Hand Eczema | completed | 235 |
| 2025-05-05 | P3 | Takeda TAK | NCT06060067 A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India | Healthy Volunteers | completed | 480 |
| 2025-05-06 est. | P2 | AstraZeneca AZN | NCT03944772 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | Non-Small Cell Lung Cancer | active not recruiting | 247 |
| 2025-05-06 | P3 | LG Chem | NCT05586971 Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients | Gout; Hyperuricemia; Gout Flare; Tophi | completed | 2202 |
| 2025-05-06 | P3 | Guerbet | NCT06010173 Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children | Lesion in Body Region; CNS Lesion | completed | 240 |
| 2025-05-06 | P2 | Nektar Therapeutics NKTR | NCT06136741 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | active not recruiting | 396 |
| 2025-05-06 | P2 | Recursion Pharmaceuticals Inc. RXRX | NCT06536465 The Clostridioides Difficile Trial of REC-3964 | Recurrent Clostridioides Difficile Infection | terminated | 3 |
| 2025-05-06 | P2 | Shanghai JunTop Biosciences Co., LTD | NCT06861101 Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults | Seasonal Allergic Rhinitis | completed | 370 |
| 2025-05-07 | P3 | AstraZeneca AZN | NCT04191304 A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | Hypereosinophilic Syndrome | active not recruiting | 134 |
| 2025-05-07 | P3 | Takeda TAK | NCT04701411 A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease | Crohn's Disease; Complex Perianal Fistula | terminated | 7 |
| 2025-05-07 est. | P3 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT05204628 A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | Non-small Cell Lung Cancer | unknown | 238 |
| 2025-05-07 | P3 | Novartis Pharmaceuticals NVS | NCT05350072 Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Sjogren Syndrome | completed | 275 |
| 2025-05-07 est. | P2 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT05482087 A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | ALK-positive NSCLC | unknown | 190 |
| 2025-05-07 | P3 | Hoffmann-La Roche | NCT05642325 Vamikibart in Participants With Uveitic Macular Edema | Uveitic Macular Edema | completed | 256 |
| 2025-05-07 | P3 | Apnimed APMD | NCT05811247 Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) | OSA | completed | 660 |
| 2025-05-07 | P3 | Alexion Pharmaceuticals, Inc. | NCT05876351 Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | Atypical Hemolytic Uremic | completed | 25 |
| 2025-05-07 | P2 | Merz Therapeutics GmbH | NCT06091020 A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic N | Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or | completed | 123 |
| 2025-05-07 | P2 | Beijing QL Biopharmaceutical Co.,Ltd | NCT07020884 A Study of ZT002 Injection With Subjects With Overweight or Obesity | Overweight or Obesity | completed | 303 |
| 2025-05-08 | P2 | Sermonix Pharmaceuticals Inc. | NCT03781063 Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Locally Advanced or Metastatic Breast Cancer | completed | 100 |
| 2025-05-08 | P3 | Zogenix, Inc. | NCT03936777 A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including D | Dravet Syndrome; Lennox Gastaut Syndrome; Epileptic Encephalopathy | completed | 412 |
| 2025-05-08 | P3 | Gamida Cell ltd | NCT04260698 Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies | Hematological Malignancies | completed | 36 |
| 2025-05-08 | P3 | Janssen Research & Development, LLC | NCT04630028 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Colitis, Ulcerative | completed | 112 |
| 2025-05-08 | P2/P3 | Cellphire Therapeutics, Inc. | NCT04709705 DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) | Cardiac Surgery | completed | 161 |
| 2025-05-08 | P2 | Mural Oncology, Inc | NCT04830124 Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 | Cutaneous Melanoma; Mucosal Melanoma | terminated | 173 |
| 2025-05-08 | P3 | Merck Sharp & Dohme LLC MRK | NCT04949256 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-0 | Metastatic Esophageal Squamous Cell Carcinoma | terminated | 863 |
| 2025-05-08 | P3 | Allergan | NCT05452070 A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participant | Mid Face Volume Deficit | completed | 171 |
| 2025-05-08 | P2 | Amgen AMGN | NCT05591222 Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus | Discoid Lupus Erythematosus | terminated | 72 |
| 2025-05-08 | P3 | Hoffmann-La Roche | NCT05904886 A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carci | Hepatocellular Carcinoma | active not recruiting | 687 |
| 2025-05-08 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06198751 A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | Breast Cancer | active not recruiting | 104 |
| 2025-05-08 | P3 | Novo Nordisk A/S NVO | NCT06340854 A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily In | Diabetes, Type 2 | completed | 412 |
| 2025-05-08 | P2 | Gilead Sciences GILD | NCT06585150 Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection | RSV Infection | terminated | 150 |
| 2025-05-08 | P2 | Evommune, Inc. EVMN | NCT06603220 A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria | Chronic Inducible Urticaria | completed | 30 |
| 2025-05-08 | P3 | Hoffmann-La Roche | NCT06774859 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms | Influenza | completed | 100 |
| 2025-05-09 | P1/P2 | Inovio Pharmaceuticals INO | NCT03502785 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | Urothelial Carcinoma | completed | 35 |
| 2025-05-09 | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05174585 JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | Solid Tumor | completed | 21 |
| 2025-05-09 est. | P2 | Ashvattha Therapeutics, Inc. | NCT05387837 Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | Neovascular Age-related Macular Degeneration; Diabetic Macular Edema | active not recruiting | 50 |
| 2025-05-09 | P2 | PharmaEssentia | NCT05482971 A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | Essential Thrombocythemia | active not recruiting | 91 |
| 2025-05-09 | P2 | Telix Pharmaceuticals (Innovations) Pty Ltd TLX | NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma Multiforme; Chol | terminated | 11 |
| 2025-05-09 | P2 | Novatek Pharmaceuticals | NCT05785390 Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. | COVID-19 | terminated | 170 |
| 2025-05-09 | P2 | AstraZeneca AZN | NCT06350123 Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease | Chronic Kidney Disease | completed | 324 |
| 2025-05-09 | P2/P3 | Cessatech A/S | NCT06364072 Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients | Pain | completed | 155 |
| 2025-05-09 | P3 | MAXVAX Biotechnology Limited Liability Company | NCT06654700 Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). | Herpes Zoster | completed | 1200 |
| 2025-05-10 | P3 | Alexion Pharmaceuticals, Inc. | NCT04504825 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | AL Amyloidosis | active not recruiting | 125 |
| 2025-05-10 est. | P2 | Gannex Pharma Co., Ltd. | NCT05462353 Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH | Non-alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis | unknown | 183 |
| 2025-05-10 est. | P2 | Kayuraeffect, LLP | NCT06473974 Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation | Facial Hyperpigmentation | withdrawn | |
| 2025-05-10 | P3 | Regeneron Pharmaceuticals REGN | NCT06602726 A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy | Allergic Conjunctivitis | completed | 64 |
| 2025-05-12 | P2 | Inmune Bio, Inc. INMB | NCT05318976 A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Disease | completed | 207 |
| 2025-05-12 | P2 | ABO Holdings, Inc. | NCT05662852 Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors | Tetanus, Diphtheria and Acellular Pertussis Vaccination | completed | 107 |
| 2025-05-12 | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT06643078 A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD | Chronic Obstructive Pulmonary Disease (COPD) | completed | 487 |
| 2025-05-12 | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT06747247 A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism | Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | completed | 98 |
| 2025-05-13 | P3 | DBV Technologies DBVT | NCT03859700 Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children | Peanut Allergy | completed | 304 |
| 2025-05-13 | P3 | Novartis Pharmaceuticals NVS | NCT05349214 Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Sjogren Syndrome | active not recruiting | 506 |
| 2025-05-13 | P3 | Beijing Mabworks Biotech Co., Ltd. | NCT05862233 A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy | Primary Membranous Nephropathy | unknown | 150 |
| 2025-05-13 | P3 | Formycon AG | NCT06643117 Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Can | Non Small Cell Lung Cancer; Non-Squamous Non-Small Cell Lung Cancer | terminated | 25 |
| 2025-05-13 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06871761 A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes | Adult Patients With Type 2 Diabetes | completed | 393 |
| 2025-05-13 | P3 | Colgate Palmolive CL | NCT06960148 Dentinal Hypersensitivity Reduction Efficacy Study | Sensitivity, Tooth | completed | 95 |
| 2025-05-14 | P1/P2 | Oncoinvent Solutions AS | NCT03732781 Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC | Peritoneal Carcinoma; Colorectal Carcinoma | completed | 47 |
| 2025-05-14 | P2 | PDS Biotechnology Corp. PDSB | NCT04260126 Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; HPV Positive Oropharyngeal Squamous | completed | 95 |
| 2025-05-14 | P2 | Omeicos Therapeutics GmbH | NCT05972954 OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) | Primary Mitochondrial Disease | completed | 28 |
| 2025-05-14 est. | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT05997602 To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH | Langerhans Cell Histiocytosis; LCH | recruiting | 56 |
| 2025-05-14 | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06161844 Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | completed | 506 |
| 2025-05-14 | P2/P3 | Beijing Protgen Biotechnology Development Co., Ltd. | NCT06553456 Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites | Cirrhotic Ascites | completed | 390 |
| 2025-05-15 | P3 | Celgene | NCT04140305 Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) | Multiple Sclerosis | terminated | 188 |
| 2025-05-15 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04691063 The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | Small-cell Lung Cancer | unknown | 486 |
| 2025-05-15 | P2 | SymBio Pharmaceuticals | NCT04706923 A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection | Adenovirus Infections; Cytomegalovirus Infection | completed | 53 |
| 2025-05-15 | P3 | Vera Therapeutics, Inc. VERA | NCT04716231 Atacicept in Subjects With IgA Nephropathy | IgA Nephropathy; Berger Disease | active not recruiting | 428 |
| 2025-05-15 | P2 | Janssen Research & Development, LLC | NCT05242484 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | active not recruiting | 577 |
| 2025-05-15 | P3 | Grünenthal GmbH | NCT05377489 Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee | Osteoarthritis | completed | 714 |
| 2025-05-15 | P3 | Novartis Pharmaceuticals NVS | NCT05456191 A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Phila | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | active not recruiting | 568 |
| 2025-05-15 | P2 | Compass Therapeutics COMP | NCT05513742 A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer | completed | 49 |
| 2025-05-15 | P3 | Conceptra Biosciences, LLC | NCT06121063 CCT-102 or Expectant Management in Delayed Pregnancy Loss | Early Pregnancy Loss, Delayed Pregnancy Loss | completed | 183 |
| 2025-05-15 | P3 | Alexion Pharmaceuticals, Inc. | NCT06578949 Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria; PNH | completed | 18 |
| 2025-05-15 est. | P2 | Healthgen Biotechnology Corp. | NCT06722664 Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa. | Gastric Mucosal Lesion | active not recruiting | 336 |
| 2025-05-16 | P3 | Alfasigma S.p.A. | NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 2731 |
| 2025-05-16 | P3 | Hutchmed HCM | NCT05029635 Phase III Study on HMPL-523 for Treatment of ITP | Primary Immune Thrombocytopenia (ITP) | completed | 272 |
| 2025-05-16 | P2 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05536414 Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 337 |
| 2025-05-16 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06471218 Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | Hyperlipidemia | completed | 44 |
| 2025-05-17 | P3 | Guangdong Longchuangji Pharmaceutical Co., Ltd. | NCT07418957 Efficacy and Safety of Vaginal Lactobacillus Dual Probiotic Capsules in Bacterial Vaginosis | Bacterial Vaginosis (BV) | completed | 402 |
| 2025-05-19 | P3 | GlaxoSmithKline | NCT05243680 An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) | Asthma | completed | 641 |
| 2025-05-19 | P1/P2 | GlaxoSmithKline | NCT05330455 Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection | Hepatitis B | terminated | 74 |
| 2025-05-19 | P3 | Ascletis Pharmaceuticals Co., Ltd. | NCT06192264 A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris | Acne | completed | 480 |
| 2025-05-19 | P3 | Hyundai Pharm | NCT06646354 To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia | Hypertension; Primary Hypercholesterolaemia | enrolling by invitation | 125 |
| 2025-05-20 | P3 | Il-Yang Pharm. Co., Ltd. | NCT04381689 Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants | Healthy | completed | 260 |
| 2025-05-20 | P2 | Prokidney PROK | NCT05018416 Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007) | Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus | completed | 53 |
| 2025-05-20 | P2/P3 | Incannex Healthcare Ltd IXHL | NCT06146101 RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA | Obstructive Sleep Apnea | completed | 121 |
| 2025-05-20 | P2 | Biomea Fusion Inc. BMEA | NCT06152042 Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | completed | 37 |
| 2025-05-20 | P2 | Neuraly, Inc. | NCT06410924 A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH | NAFLD; NASH | completed | 67 |
| 2025-05-20 | P3 | Dexa Medica Group | NCT06558071 Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers | Lactation Induced | completed | 160 |
| 2025-05-20 | P1/P2 | AeroRx Therapeutics Inc. | NCT06841640 Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD | COPD | completed | 24 |
| 2025-05-20 | P1/P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT07102706 Phase I Trial of GR1803 Injection in Patients With RRMM | Multiple Myeloma (MM) | completed | 76 |
| 2025-05-21 | P2 | Merck Sharp & Dohme LLC MRK | NCT04895722 Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatc | Colorectal Cancer | completed | 302 |
| 2025-05-21 | P2 | Novartis Pharmaceuticals NVS | NCT05172596 PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | terminated | 146 |
| 2025-05-21 | P2 | River 3 Renal Corp. | NCT05267262 Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis | Alport Syndrome; Focal Segmental Glomerulosclerosis | completed | 43 |
| 2025-05-21 | P3 | AstraZeneca AZN | NCT06034743 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants Wi | Uncontrolled Hypertension; Resistant Hypertension | completed | 796 |
| 2025-05-21 | P3 | Incyte Corporation INCY | NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 241 |
| 2025-05-21 | P2 | Island Pharmaceuticals | NCT06528457 Study to Examine the Effects of Oral Fenretinide | Dengue | completed | 15 |
| 2025-05-22 | P2 | Bristol-Myers Squibb BMY | NCT04702880 A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer | completed | 135 |
| 2025-05-22 | P2 | Cogent Biosciences, Inc. COGT | NCT05186753 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | SSM; Mastocytosis, Indolent; Mastocytosis, Systemic; Mastocytosis; ISM; BMM; Smoldering Systemic Mas | active not recruiting | 237 |
| 2025-05-22 | P2 | AstraZeneca AZN | NCT05516498 Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) | Liver Cirrhosis | terminated | 205 |
| 2025-05-22 | P1/P2 | GlaxoSmithKline | NCT05630859 Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age | Sexually Transmitted Diseases | completed | 1009 |
| 2025-05-22 | P2 | NexEos Diagnostics, Inc. | NCT05757856 A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | completed | 34 |
| 2025-05-22 | P3 | Kowa Research Institute, Inc. | NCT05795699 A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) | Fuchs Endothelial Corneal Dystrophy | completed | 107 |
| 2025-05-22 | P2 | Reunion Neuroscience Inc | NCT06342310 RE104 Safety and Efficacy Study in Postpartum Depression | Postpartum Depression | completed | 84 |
| 2025-05-23 est. | P1/P2 | Editas Medicine, Inc. EDIT | NCT03872479 Single Ascending Dose Study in Participants With LCA10 | Leber Congenital Amaurosis 10; Inherited Retinal Dystrophies; Eye Diseases, Hereditary; Retinal Dise | unknown | 34 |
| 2025-05-23 | P2 | Janssen Research & Development, LLC | NCT05242471 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | active not recruiting | 703 |
| 2025-05-23 | P2 | Lumosa Therapeutics Co., Ltd. | NCT05403866 A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects | Acute Ischemic Stroke | completed | 89 |
| 2025-05-23 est. | P1/P2 | Imcyse SA | NCT05417269 IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study | Multiple Sclerosis, Relapsing-Remitting | unknown | 150 |
| 2025-05-23 | P1/P2 | BeiGene | NCT05609370 A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizuma | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | active not recruiting | 113 |
| 2025-05-23 | P2 | Soligenix SNGX | NCT06386744 Dusquetide for the Treatment of Behcet's Disease | Behçet Disease | completed | 8 |
| 2025-05-23 | P3 | RDC Clinical Pty Ltd | NCT06436781 Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population | Post Exercise Inflammation; Exercise Recovery; Muscle Fatigue; Muscle Pain | completed | 33 |
| 2025-05-23 | P2 | MBX Biosciences MBX | NCT06465108 Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism | Hypoparathyroidism | completed | 64 |
| 2025-05-23 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors | HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors | terminated | 11 |
| 2025-05-25 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06344065 Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants | Healthy Volunteers | recruiting | 1584 |
| 2025-05-25 | P2 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT06795399 A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure | Heart Failure | withdrawn | |
| 2025-05-26 | P3 | SK Life Science, Inc. | NCT03678753 Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures | Primary Generalized Epilepsy | completed | 169 |
| 2025-05-26 | P3 | Celgene | NCT04717414 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 | Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis; Post-Polycythemia Vera Myelofibr | active not recruiting | 313 |
| 2025-05-26 | P2 | Santen Inc. | NCT05376176 A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelia | Fuchs Endothelial Corneal Dystrophy | completed | 86 |
| 2025-05-26 | P1/P2 | ACELYRIN Inc. | NCT05683496 Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) | Thyroid Eye Disease | completed | 31 |
| 2025-05-26 | P2 | Ausper Biopharma Co., Ltd. | NCT06550128 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). | Hepatitis B, Chronic | completed | 86 |
| 2025-05-26 | P2 | Prime Gene Therapeutics Co., Ltd. | NCT06837233 A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | completed | 179 |
| 2025-05-27 | P2 | Clene Nanomedicine CLNN | NCT03993171 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. | Multiple Sclerosis | completed | 33 |
| 2025-05-27 | P3 | Hoffmann-La Roche | NCT04513925 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC | Non-small Cell Lung Cancer (NSCLC) | completed | 829 |
| 2025-05-27 | P2 | GlaxoSmithKline | NCT05382312 Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Car | Tuberculosis | completed | 127 |
| 2025-05-27 | P3 | Alexion Pharmaceuticals, Inc. | NCT05556096 Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | active not recruiting | 260 |
| 2025-05-27 | P1/P2 | BeiGene | NCT05661955 A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Sele | Urothelial Carcinoma; Renal Cell Carcinoma; Melanoma; Non-mucosal Melanoma | active not recruiting | 113 |
| 2025-05-27 | P3 | Novo Nordisk A/S NVO | NCT06269107 A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People Wi | Type 2 Diabetes | completed | 485 |
| 2025-05-27 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06619847 A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy | Acute Pain | completed | 367 |
| 2025-05-27 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06631170 Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 354 |
| 2025-05-27 | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07093697 A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212 | Acute Bronchitis | completed | 273 |
| 2025-05-28 | P1/P2 | Intima Bioscience, Inc. | NCT04426669 A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH I | Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Ca | completed | 23 |
| 2025-05-28 | P1/P2 | Vor Biopharma VOR | NCT04849910 Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MD | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | terminated | 67 |
| 2025-05-28 | P2 | Amgen AMGN | NCT04933695 A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment | Non-small Cell Lung Cancer | terminated | 42 |
| 2025-05-28 | P2 | Organon and Co OGN | NCT05560646 A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometri | Endometriosis | completed | 354 |
| 2025-05-28 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05563480 TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | completed | 47 |
| 2025-05-28 | P3 | COMPASS Pathways CMPS | NCT05624268 Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Treatment Resistant Depression | completed | 258 |
| 2025-05-28 | P3 | Laboratoire français de Fractionnement et de Biotechnologies | NCT05695391 Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery | Hemophilia | terminated | 2 |
| 2025-05-28 | P1/P2 | Vor Biopharma VOR | NCT05984199 Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | Leukemia, Myeloid, Acute | terminated | 38 |
| 2025-05-28 | P1/P2 | BioNTech SE BNTX | NCT06069544 A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria | Malaria | completed | 163 |
| 2025-05-28 | P3 | Novartis Pharmaceuticals NVS | NCT06236061 Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy | Hypertension | completed | 718 |
| 2025-05-28 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06649773 The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients | Type 2 Diabetes | completed | 137 |
| 2025-05-28 | P2 | PepGen Inc PEPG | NCT06833931 A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | Duchenne Muscular Dystrophy (DMD) | withdrawn | |
| 2025-05-29 | P2 | EIP Pharma Inc | NCT05869669 RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Dementia With Lewy Bodies | completed | 159 |
| 2025-05-29 | P2 | Owlstone Ltd | NCT06193239 Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution Phase 2) | Lung Cancer | completed | 187 |
| 2025-05-29 | P3 | AO GENERIUM | NCT06497491 An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease | Still's Disease Adult Onset | completed | 118 |
| 2025-05-30 | P3 | Takeda TAK | NCT04738942 A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease | Ulcerative Colitis; Crohn's Disease | active not recruiting | 56 |
| 2025-05-30 | P3 | BeiGene | NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Non-small Cell Lung Cancer; NSCLC | terminated | 669 |
| 2025-05-30 | P2 | Bayer | NCT05059236 A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Can | Metastatic Hormone-sensitive Prostate Cancer | completed | 223 |
| 2025-05-30 | P3 | IO Biotech | NCT05155254 IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | Metastatic Melanoma; Unresectable Melanoma | active not recruiting | 407 |
| 2025-05-30 | P2 | Fusion Pharmaceuticals Inc. HTOO | NCT05219500 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). | Metastatic Castration Resistant Prostate Cancer | active not recruiting | 115 |
| 2025-05-30 | P3 | Janssen Research & Development, LLC | NCT05272150 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis | Plaque Psoriasis; Scalp Psoriasis | completed | 211 |
| 2025-05-30 | P1/P2 | Enterome | NCT05589597 EO4010 in Previously Treated Metastatic Colorectal Carcinoma | Colorectal Cancer Metastatic | terminated | 25 |
| 2025-05-30 | P1/P2 | Juventas Cell Therapy Ltd. | NCT05667506 A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | B-cell Acute Lymphoblastic Leukemia | recruiting | 47 |
| 2025-05-30 | P2 | AbbVie ABBV | NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | terminated | 81 |
| 2025-05-30 | P1/P2 | ModernaTX, Inc. | NCT05975099 A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | Lyme Disease | completed | 807 |
| 2025-05-30 | P3 | Pfizer PFE | NCT05989048 A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults | Migraine | completed | 1414 |
| 2025-05-30 | P2 | BeiGene | NCT06010303 A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squam | Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma by AJCC V8 | completed | 118 |
| 2025-05-30 | P2 | Eli Lilly and Company LLY | NCT06230523 A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity; Overweight | completed | 263 |
| 2025-05-30 est. | P1/P2 | GeneMedicine Co., Ltd. | NCT06265025 GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | Head and Neck Cancer; Malignant Melanoma; Colorectal Cancer; Renal Cell Carcinoma; Cervical Cancer; | recruiting | 125 |
| 2025-05-30 | P2/P3 | Bio-Thera Solutions | NCT06321068 BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | Endometrial Cancer | terminated | 5 |
| 2025-05-30 est. | P1/P2 | Canwell Biotech Limited | NCT06410703 CAN1012 Combined With PD-1 in Patients With Solid Tumors | Advanced Solid Tumor | unknown | 71 |
| 2025-05-30 | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06481085 To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | completed | 324 |
| 2025-05-30 | P3 | Addpharma Inc. | NCT06747936 A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282 | Primary Hypercholesterolemia | completed | 129 |
| 2025-05-31 est. | P3 | Jina Pharmaceuticals Inc. | NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | Triple Negative Breast Cancer | recruiting | 657 |
| 2025-05-31 est. | P3 | Liquidia Technologies, Inc. LQDA | NCT03992755 Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil | Primary Pulmonary Hypertension | active not recruiting | 92 |
| 2025-05-31 | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT04911907 Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors | Solid Tumor | completed | 126 |
| 2025-05-31 est. | P3 | Hutchison Medipharma Limited | NCT05015621 A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | unknown | 194 |
| 2025-05-31 | P2 | Cardurion Pharmaceuticals, Inc. | NCT06005428 Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | CPVT1; Heart Defects, Congenital; Heart Diseases; Ventricular Tachycardia | terminated | 7 |
| 2025-05-31 | P3 | Ferring Pharmaceuticals | NCT06173869 A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU | Infertility, Female | completed | 301 |
| 2025-05-31 est. | P2 | Changchun BCHT Biotechnology Co. | NCT06548139 Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials | Rabies Virus Infection | unknown | 120 |
| 2025-05-31 est. | P3 | Macleods Pharmaceuticals Ltd | NCT06618105 Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Ma | Mild Asthma | unknown | 144 |
| 2025-05-31 est. | P2/P3 | Shanghai Mabgeek Biotech.Co.Ltd | NCT06846385 Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | recruiting | 160 |
| 2025-05-31 | P1/P2 | AO GENERIUM | NCT07155499 A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V | Rhinitis, Allergic, Seasonal | completed | 150 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.